PF612 ONCE WEEKLY (70 MG/M2) VERSUS TWICE WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Background:Carfilzomib (CFZ) combined with dexamethasone is approved to treat patients (pts) with relapsed and/or refractory multiple myeloma (RRMM), with CFZ given once-weekly at 70 mg/m 2 (Kd70 QW) or twice-weekly at 56 mg/m 2 (Kd56 BIW). No randomized trials have directly compared Kd70 QW with Kd56 BIW.Aims:We performed a post hoc comparison between pts who received Kd56 BIW in the ENDEAVOR trial and pts who received Kd70 QW in the ARROW or CHAMPION-1 trials.Methods:Data were analyzed from 3 trials of CFZ in RRMM: ARROW (240 pts in Kd70 QW arm; 2–3 prior therapies and refractory to most recent therapy), CHAMPION-1 (104 pts received Kd70 QW; 1–3 prior therapies), and ENDEAVOR (464 pts in Kd56 BIW arm; 1–3 prior therapies). Pts who received Kd70 QW in ARROW and CHAMPION-1 were pooled and compared with pts who received Kd56 BIW in ENDEAVOR. As …